Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Access via DeepDyve
Unlimited fulltext viewing Of this article
Organize, annotate And mark up articles
Printing And downloading restrictions apply
Select
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) are expected to improve the prognosis of gastric cancer (GC). On the other hand, hepatic steatosis has been reported to be associated with cancer cachexia, and expected to be a cancer biomarker. The purpose of this study is to evaluate prognostic impact of hepatic steatosis in ICIs therapy for GC.
Methods: Unresectable or recurrent GC treated with ICIs were investigated. Using unenhanced CT, liver to spleen CT attenuation ratio (LSR) was calculated as a parameter of hepatic steatosis. LSR was compared with the presence of sarcopenia, inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). These parameters were also compared with disease specific survival (DSS) and progression free survival (PFS). Associations of LSR with insulin-like growth factor 1 (IGF-1) and growth hormone were also evaluated.
Results: A total of seventy patients were investigated. LSR of sarcopenia patients was significantly lower than that of non-sarcopenia ones (P=0.02). LSR showed significant negative correlations with NLR, PLR, and MLR (P=0.003, 0.03, 0.01, respectively). Lower LSR was significantly associated with higher level of serum IGF-1 (P=0.03). In univariate analysis, LSR was significantly correlated with DSS and PFS (both P1.263 was a good predictive marker for favorable DSS (>5.3 months) with AUC of 0.80.
Conclusion: Hepatic steatosis can be a promising prognostic biomarker for ICIs therapy of GC, associated with sarcopenia and the elevation of inflammatory markers. Out data suggested that GC with steatohepatitis might be less responsive to ICIs therapy.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)